Harvard Pilgrim, Lilly partner on Trulicity outcomes

Under a deal with regional payer Harvard Pilgrim Health Care Inc. (Boston, Mass.), the reimbursement and rebate amount for diabetes drug Trulicity dulaglutide from Eli Lilly and Co. (NYSE:LLY) will hinge on

Read the full 329 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE